Sound Biologics

Platform enabling the production of two distinct monoclonal antibodies as a single drug product, designed to combine multi-pathway therapeutic activity while simplifying administration and reducing cost versus separate antibody cocktails.

Platform for generating stable heterodimeric bispecific antibodies suited for expression and purification using standard antibody production methods.

PSB205 is a first-in-class, bifunctional therapy composed of a precisely defined mixture of unique anti-PD-1 and anti-CTLA-4 monoclonal antibodies, co-produced from a single cell line using proprietary MabPair technology. It is engineered for optimized target coverage, effector function, pharmacokinetics, and exposure, with the CTLA-4 component having a shorter half-life to reduce toxicities. PSB205 has demonstrated superior antitumor activity in preclinical models and is in advanced clinical development for multiple cancers.

A technology platform to produce next-generation therapeutic antibodies targeting multiple molecules and pathways, enabling custom-designed antibody combinations to reduce tumor escape and drug resistance.

QLP3119/PSB219 is a novel biological entity consisting of two humanized monoclonal antibodies: an anti-TSLP IgG1 and an anti-IL-33 IgG4 designed to target and inhibit proinflammatory cytokines TSLP and IL-33 involved in severe asthma and COPD.

PSB114 is a glycoengineered anti-CCR8 antibody designed to selectively deplete CCR8⁺ regulatory T cells that suppress immune responses within the tumor microenvironment, enhancing antitumor immunity with improved safety and specificity.